Vitality Biopharma enters $5M equity line at 85% discount with warrants

RANGE IMPACT, INC.

Shares sold at 85% of lowest 5-day VWAP; warrants at 115% of same VWAP.
Drawdowns limited to $250K per notice; financing expires Dec 31, 2022 or $5M total.
Proceeds to advance VBX-100 prodrug preclinical studies and general corporate purposes.
VBX-100 granted FDA Orphan Drug Designation for pediatric ulcerative colitis.
Institutional investor's beneficial ownership capped at 9.99% for shares, 4.99% for warrants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.